- In 2018, the National Cancer Institute estimates there will be 1,735,000 new cases of cancer diagnosed in the U.S.
- During the past 12 months, health care ads have reached 75% of U.S. cancer survivors on television, 54% at doctor’s offices and 40% via magazines.
- When asked what sources of information they value the most, it’s no surprise that all survivors look primarily to their medical support team (doctors, nurses, pharmacists), medication packaging/labels and family/friends.
- Oncology DTC ads promise a lot, but the therapies are not right for everyone.
- Many of these treatments bring risks of painful — even life-threatening— side effects and carry total price tags pushing $1 million.
- There are few objective guideposts to determine which patients should get which treatments, or even undergo genetic testing to determine whether they are among the minority of patients who might benefit substantially from immuno-oncology medicines. (Source:STAT News)
KEY TAKEAWAY:According to PBS.org surprisingly, huge numbers of cancer patients lack basic information, such as how long they can expect to live, whether their condition is curable or why they’re being prescribed chemotherapy or radiation, said Dr. Rab Razzak, director of outpatient palliative medicine at Johns Hopkins Medicine in Baltimore. The result: People with advanced cancer don’t know enough about their disease to make informed decisions about treatment or how they want to spend their remaining time. But is the new DTC for Oncology products, adding to the confusion? Continue reading